Stock 603387 GETEIN BIOTECH, INC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Getein Biotech, Inc

Equities

603387

CNE100002RR9

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
9.04 CNY +0.44% Intraday chart for Getein Biotech, Inc +4.75% -17.82%
2023 Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 7,917 4,942 6,002 8,911 7,254 6,339
Enterprise Value (EV) 1 6,982 3,911 4,960 7,900 6,169 5,773
P/E ratio 34.9 x 19.8 x 17.7 x 29.3 x 18.2 x 12.8 x
Yield 0.75% 1.54% 1.74% 1.05% 1.7% 2.72%
Capitalization / Revenue 16.2 x 7.2 x 6.2 x 7.93 x 5.18 x 3.48 x
EV / Revenue 14.3 x 5.7 x 5.12 x 7.03 x 4.4 x 3.17 x
EV / EBITDA 31.9 x 14.8 x 13.4 x 23 x 13.5 x 10.5 x
EV / FCF 85.8 x 331 x 5.64 x -78.3 x 53.4 x -20.9 x
FCF Yield 1.17% 0.3% 17.7% -1.28% 1.87% -4.78%
Price to Book 6.92 x 3.67 x 3.69 x 4.82 x 3.45 x 2.55 x
Nbr of stocks (in thousands) 507,091 510,419 510,345 510,268 506,279 507,154
Reference price 2 15.61 9.683 11.76 17.46 14.33 12.50
Announcement Date 4/10/18 4/9/19 3/23/20 4/28/21 4/27/22 4/26/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 488.6 686.2 968.2 1,123 1,402 1,822
EBITDA 1 218.9 265.2 370.7 342.7 457 549.9
EBIT 1 198 240.7 343.3 307.5 409.6 485.9
Operating Margin 40.52% 35.08% 35.46% 27.37% 29.22% 26.67%
Earnings before Tax (EBT) 1 224 287.3 396 374 451.6 560
Net income 1 194 249.6 339.7 304.7 399 498.9
Net margin 39.7% 36.37% 35.08% 27.13% 28.46% 27.38%
EPS 2 0.4477 0.4883 0.6633 0.5969 0.7857 0.9800
Free Cash Flow 1 81.4 11.81 878.7 -100.8 115.6 -276.2
FCF margin 16.66% 1.72% 90.75% -8.98% 8.24% -15.16%
FCF Conversion (EBITDA) 37.19% 4.45% 237.01% - 25.29% -
FCF Conversion (Net income) 41.96% 4.73% 258.69% - 28.96% -
Dividend per Share 2 0.1171 0.1494 0.2041 0.1837 0.2429 0.3400
Announcement Date 4/10/18 4/9/19 3/23/20 4/28/21 4/27/22 4/26/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 935 1,031 1,042 1,012 1,085 566
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 81.4 11.8 879 -101 116 -276
ROE (net income / shareholders' equity) 26% 19.8% 22.8% 17.9% 19.3% 20.4%
ROA (Net income/ Total Assets) 14.5% 10.6% 12% 8.16% 8.77% 8.91%
Assets 1 1,333 2,354 2,832 3,732 4,549 5,598
Book Value Per Share 2 2.250 2.640 3.180 3.620 4.150 4.890
Cash Flow per Share 2 0.5900 0.2800 1.290 1.580 1.910 1.270
Capex 1 61.4 111 125 114 180 217
Capex / Sales 12.56% 16.14% 12.89% 10.11% 12.81% 11.94%
Announcement Date 4/10/18 4/9/19 3/23/20 4/28/21 4/27/22 4/26/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
GETEIN BIOTECH, INC Stock Getein Biotech, Inc
-17.82% 633M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 603387 Stock
  4. Financials Getein Biotech, Inc